![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » GW PHARMA JUMPS ON EUROPEAN DEAL FOR CANNABIS DRUG
GW PHARMA JUMPS ON EUROPEAN DEAL FOR CANNABIS DRUG
December 12, 2005
GW Pharmaceuticals has agreed a deal for Spain's Almirall to market its pioneering cannabis-based medicine, Sativex, in European countries excluding the UK, sending its shares higher on Monday. GW Pharma said it would receive a signature fee of 12 million pounds, within total potential milestone payments of 46 million pounds, and that it would maintain a significant share of long-term product revenues.
Scotsman (http://business.scotsman.com/latest.cfm?id=2392172005)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct